PROCREA BIOSCIENCES INC. – Trademark Portfolio

Entity Type: 03

PROCREA BIOSCIENCES INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 8 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. The owner is based in Montreal, Province of Quebec.

1100 Beaumont Street

Suite 305

Montreal, Province of Quebec H3P 3H5 , CA

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

PROCREA BIOSCIENCES INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (8 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does PROCREA BIOSCIENCES INC. have?

PROCREA BIOSCIENCES INC. has 10 U.S. trademarks filed with the USPTO.

What trademark classes does PROCREA BIOSCIENCES INC. file in?

PROCREA BIOSCIENCES INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.

What is PROCREA BIOSCIENCES INC.'s trademark registration success rate?

PROCREA BIOSCIENCES INC. has a 0% trademark registration rate, with 0 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.